Tempus AI, Inc. - Class A (TEM)

Risk management mandates strict monitoring of regulatory exposure, particularly concerning FDA oversight of laboratory-developed tests (LDTs) and artificial intelligence/machine learning-based software as a medical device (SaMD). Any tightening of validation requirements across diagnostic platforms could increase compliance overhead and delay product rollout timelines across international jurisdictions.

From a quantitative volatility perspective, TEM exhibits high sensitivity to macroeconomic risk sentiment shifts regarding unprofitable growth equities. Implied volatility tends to remain elevated relative to realized volatility due to structural uncertainty around path-to-profitability timelines and regulatory evolution in AI diagnostics. Systematic strategies on our desk typically favor volatility selling via structured collar strategies during consolidation phases.

Watching the structural options skew on TEM, we note persistent demand for downside protection via intermediate-term put options, reflecting institutional nervousness around cash burn and regulatory headwinds in digital health. Call open interest concentrates around structural strike milestones tied to expected enterprise contract announcements, but delta-hedging flows frequently amplify intraday momentum swings.

Looking at this book from a fundamental long/short healthcare perspective, TEM is a classic high-beta secular growth vehicle. The biopharma services segment provides a predictable recurring revenue floor, but clinical diagnostics remain exposed to fee-for-service reimbursement degradation. We look for pullbacks driven by broader sector macro rotation to build core long exposure, utilizing out-of-the-money put spreads to hedge against broader life-science funding contractions.

Our bioinformatics pipelines rely heavily on structured real-world evidence for synthetic control arms and post-marketing surveillance. Tempus stands out due to the depth of its multimodal linkages—pairing genomic variants directly with longitudinal radiology and clinical response data. The sustainability of their biopharma partnerships depends on their ability to continually prove predictive validity over retrospective bias.

From a genomic data architecture standpoint, Tempus has successfully solved the messy ingestion problem by standardizing unstructured clinical notes alongside high-throughput NGS data. The true academic and commercial value lies in their longitudinal outcome tracking. If they can maintain exclusive access to these specialized cohorts without running afoul of institutional data-sharing pushback from major academic medical centers, the data moat is structurally defensible.